Here, we demonstrate that treatment with exoASO-STAT6, a novel exosome-based targeted gene silencing approach to induce TAM reprogramming, results in remodeling of the TME and robust monotherapy activity in preclinical tumor models. The gene discussed is STAT6; the disease is neoplasm.